{"name":"Syros Pharmaceuticals","slug":"syros-pharmaceuticals","ticker":"SYRS","exchange":"NASDAQ","domain":"syros.com","description":"Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.","hq":"Cambridge, MA","founded":0,"employees":"68","ceo":"","sector":"Oncology / Hematology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$5,366","metrics":{"revenue":1982000,"revenueGrowth":290.2,"grossMargin":0,"rdSpend":108153000,"netIncome":-164574000,"cash":58275000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxNX29yQkpsdG5QUDI5TVV3NFhqWmwtUUxEYnQ0dDNJWm9OOTlaXzU4NS1vOUw0emx1aFZ5THVESm5yWUFpajhIQUxxR21SQXBVUTJTNkZPaXJBQjJKQXV3Ri15M3NTOExnb1Q2WnROdUxKTk00RXdBbUxKNmVOWWFiSXZaYkpIbEhUNmpqVFRTZm5iM1Q0bzZJNktneklEZ0Y3RlFudHh6T3pqSVJhdVpSSmF2X1pMM0VqSEp0RjJGSlUwdks1N2RDUF9xMERtU2NPTkJtdVRMTnh6U2ViVEhiUEhwWTh3ckRjNVJtWG91MzAyWnJCdmQ3VjY2WmtlWC1FWmY0WmJReDlBek0?oc=5","date":"2025-07-16","type":"pipeline","source":"GlobeNewswire","summary":"Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital - GlobeNewswire","headline":"Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNMlc3VnBOMmtwdF9RTXhVWUxrVEQ1OXQ1MWJYYlU1bVFwNlJyLUU3VTk5NWN1WVM4dUU3QWZXc0I0STZoZENFVGNSRXVsR21GcXBhNGwwNVpIQ2pfVVdTLVNnVzBQaEpaWG1uVWtlMXMwMG9xeE1SaThrVGRpMU92OUdxTU5TaW9XTjhfSGF4amVRcjY5NzFsYS1kSzZGYTRCNGhHWHFCV2pUek5YbkRtbUxNNm85cy1kNnVyMXVEUVY0NHRaOEpXMDg2U0hrRUJmZUdsUFZtdFdtSllGblVBcEV0X0FlYXhibkE?oc=5","date":"2025-04-15","type":"trial","source":"PR Newswire","summary":"Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials - PR Newswire","headline":"Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOWWdYalBCQnhLeC1KaHN4d2Q3OUhxTXB1bVhlRFZrWkFpVGc3WGxsMWhJUlU4YkktTnZILXFqSUhuTEphV0hmREdfQnM0Zk1ha09zeW1xYTBBaVUtMF91VXdZV0lJWXJWTmFpWTZYcEZ2SXd1UHY1M0hsWXlBbF9nMTF3?oc=5","date":"2025-04-14","type":"deal","source":"The Pharma Letter","summary":"Syros Pharma pulls out of deal with RaQualia - The Pharma Letter","headline":"Syros Pharma pulls out of deal with RaQualia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQLWR2aExBZjJwVUk1Z2c1b1VhLWtMZnU3WTBHc2RwX3ptbzJ1S2xLVTl1LVBIQ21RRnloZjBycFh4UDBhb2laVVZQVjN1dk5NamxZM1E1MU1EWFZfUW9ERWtoMFdVYTFtaGwwc1FPSzRodkdVVXFkZ3lpdl83TGUzUGlUblE1elhtajlucG1EckZ4SC16THVQdXNZNk8xN3dwMHVhem94TEk2SkVZMHI4?oc=5","date":"2025-03-04","type":"pipeline","source":"Investing.com","summary":"Syros Pharmaceuticals settles debt with Oxford Finance - Investing.com","headline":"Syros Pharmaceuticals settles debt with Oxford Finance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxONlZtNEx2dnA2c2pwUGY5Zm8tWHR6TVF1RWVxMlJwUkplSFYtVmNCQl8xZXlvVDRldTRqSVY4UjZKUTh1RUlwVjExVkFxMkttakZNNjZCQ05meEpfTlpyTTVrM3BQZWdYQkR4VDVxd2ZkVWhjUVJmbmNLSFJPSGRrQXM1WkNhNlhqblRDcjZ3?oc=5","date":"2025-03-03","type":"trial","source":"Oncology Pipeline","summary":"Hello BridgeBio, farewell Syros and Achilles | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Hello BridgeBio, farewell Syros and Achilles | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPUjNubHpzZzliR2h4TlpDV29CSVNGWWJhMEdDRWU1NFY5UGRkNW5pdm84U2FwdHB6bDViSktHZ3BpRFNNV1dGS082TDZncVVod3RmdWhLajFsZk1TZW81QUpRVXBTbmNNOEY1Wkl0dnZaS3A3MER1V0F3a2pUZjlocWRLQkktZjJjRXRmVk9VdHFKdlhOVXd6VWg1UFFtdUtqeFVfNU10Q29maXNmU3kwcnVQMFZ1ajc3ZGJn?oc=5","date":"2024-11-13","type":"trial","source":"Fierce Biotech","summary":"Syros flunks phase 3 blood cancer trial, triggering loan default and share-price plunge - Fierce Biotech","headline":"Syros flunks phase 3 blood cancer trial, triggering loan default and share-price plunge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQbjRibEdBZGotcEliNTFGZmNqUjRKZDdDWl9kaFYxdGdnN0JIZ3ZCNEEwMjlMWURFZEg3X1d1U3gyemR6eWV3eHdDUWVWazRrYm51MjJNSTMzVW0tMkJiX0NwcEdRUUNDRV82YXhRcGJpS2pmcExJRmZheDhBR1E3NC1iSGJud0Ewc0hTOHg0bmtyN0ctUmQ4Zm1RNGItUmpn?oc=5","date":"2024-11-13","type":"pipeline","source":"BioSpace","summary":"Syros Crashes Over 90% on Late-Stage MDS Fail, Loan Default - BioSpace","headline":"Syros Crashes Over 90% on Late-Stage MDS Fail, Loan Default","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOOWxxRm9VcW5EXzhBaVRYMERkeVBWejFhd201SXJsODlwZW9fZlhlb0F0VzBTZjR3WU9iZS1OMkc4M2RzeWVyRklyUTh3QnlfZER0V1VHeDBpcnc3WjBBMlRGYXBsV21lOTBxZWJPQWR6SGxKMmFBTTFaWkc1N05pX3N4OS1SbTVPNEVFUmp2VGRiRDRuSE1nbTJZYTIyUVY5RmV4QVlCbkQtM2tiQ2tlNENnMXJ3cHlQVzZ5bw?oc=5","date":"2024-11-13","type":"trial","source":"Pharmaceutical Technology","summary":"Syros stock craters after lead cancer therapy flops in Phase III trial - Pharmaceutical Technology","headline":"Syros stock craters after lead cancer therapy flops in Phase III trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxOR1plRndJV2lLZ3FPT1Q1SHR0Q0Z0aGx6ZTJtV2pSNFZlYzJ6N1pUYU5QNFh3ZmVSVkJFWERuc0REWWs5b1hiX1g1Tjh1MGgySk15aExHdHQ4NGJEZG82VWk2T0YzLWhZT0NuUWxYS1dFSzM3ZzZZNmVJYU8tQnFvUEdnb3UwZ19uWEd2T3BIM2F0V2dtOHpKWDNyZjZwMnh5eTlYOV9FSndmdFZzZGdwZC1ZVlVhX2xXOXVKRGQ1TC1hQmxsQ2h3aGk4ZXBXZ0NYWVdSMFJDVU93bVI4RU83bldOWXV0am9zajhDcWQwZlFYNW8?oc=5","date":"2023-12-18","type":"pipeline","source":"Business Wire","summary":"Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants - Business Wire","headline":"Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNSHY3U2NUaW9jOWxkeDFhU2hQUDh2MXpDZGNTVDBGdFpHMTVtb244ZDh1MDBWeGl2b21qTGhDX29KbjVDRUxKZ2pvcHpVVGNFZ3REQ2lUQktDbERJeDZGb0pjVXFnTTNfOFpncEUwT1F1bzh1OU1rSmZBRVQtSTBKREU5QkZxUzRjc1VGeFo2SWxSVE02RkE0RzVrQ2JISlgyYUwtUjNNM2MybWhqMlBPOUFmMDY4TXNOQjEzX3RB?oc=5","date":"2022-09-16","type":"deal","source":"Faegre Drinker Biddle & Reath LLP","summary":"Tyme Technologies Completes Merger With Syros Pharmaceuticals - Faegre Drinker Biddle & Reath LLP","headline":"Tyme Technologies Completes Merger With Syros Pharmaceuticals - Faegre Drinker Biddle & Reath LLP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQbU1JMEVFWEwxQTNuZ3hfNFh0cXZ4T1NzTTlZcERtWW42dGNTZlQtR0V2YWpuaENiOHlLNFJ3VkI3VUNyNTV1TW9LQ25WTWRZSDAzMHpxZkhoTzl3ajZsMFpGd0poQUdFZlpFSjNLTEtVUnJaZHVLV29BbWQ4U2JmZXI1MFAyRVNtd1FZ?oc=5","date":"2022-07-05","type":"deal","source":"Yahoo Finance","summary":"TYME Technologies Shares Surge On Merger Agreement With Syros Pharma - Yahoo Finance","headline":"TYME Technologies Shares Surge On Merger Agreement With Syros Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOcXowM1pjYlFJSjN4b2tON0hCNU5Gc2E3cHBjbjZKMlRWQndsSEpXTnRTYkNncDY2YWdRS1JtQTJzdnBlWjBabElELUo2dEFBU09VWkI0WGlCTGlXblE4UmdUSzd6VDRjRGZNUENrd05jVHRJQnNITGd4eUFxcTA2UlloUGhhVmpPQ3NyOWhjVW93RThJLXk2S1U5NE1QOUF6RHFFcU5tSlRsX2pQbWJXZzcwQQ?oc=5","date":"2022-07-05","type":"pipeline","source":"BioPharma Dive","summary":"Two cancer biotechs merge, raise cash as sector-wide downturn continues - BioPharma Dive","headline":"Two cancer biotechs merge, raise cash as sector-wide downturn continues","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":1982000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":1982000,"period":"2019-12-31"},{"value":508000,"period":"2019-12-31"},{"value":558000,"period":"2019-09-30"},{"value":462000,"period":"2019-06-30"},{"value":454000,"period":"2019-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":108153000,"rdSpendHistory":[{"period":"2023-12-31","value":108153000},{"period":"2022-12-31","value":111944000},{"period":"2021-12-31","value":99872000}],"sgaSpend":28282000,"operatingIncome":-126499000,"operatingIncomeHistory":[{"period":"2023-12-31","value":-126499000},{"period":"2022-12-31","value":-126363000},{"period":"2021-12-31","value":-99420000}],"netIncome":-164574000,"netIncomeHistory":[{"period":"2023-12-31","value":-164574000},{"period":"2022-12-31","value":-94654000},{"period":"2021-12-31","value":-86558000}],"eps":-5.81,"epsHistory":[{"period":"2023-12-31","value":-5.81},{"period":"2022-12-31","value":-7.49},{"period":"2021-12-31","value":-13.84}],"cash":139526000,"cashHistory":[{"period":"2023-12-31","value":139526000},{"period":"2022-12-31","value":167467000},{"period":"2021-12-31","value":92302000}],"totalAssets":168174000,"totalLiabilities":151512000,"totalDebt":62075000,"equity":16662000,"operatingCashflow":-109707000,"operatingCashflowHistory":[{"period":"2023-12-31","value":-109707000},{"period":"2022-12-31","value":-123065000},{"period":"2021-12-31","value":-99540000}],"capex":-272000,"capexHistory":[{"period":"2023-12-31","value":-272000},{"period":"2022-12-31","value":-1241000},{"period":"2021-12-31","value":-1245000}],"freeCashflow":-109979000,"dividendsPaid":null,"buybacks":0,"employees":68,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":5655000,"ebit":-5084000,"ebitda":-4759000,"period":"2024-09-30","revenue":0,"epsBasic":-0.16,"netIncome":-6396000,"rdExpense":20527000,"epsDiluted":-0.16,"grossProfit":null,"operatingIncome":-26182000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0,"previousClose":0,"fiftyTwoWeekHigh":0.04,"fiftyTwoWeekLow":0,"fiftyTwoWeekRange":"1.0E-4 - 0.04","fiftyDayAverage":0,"twoHundredDayAverage":0,"beta":1.26,"enterpriseValue":1956366,"forwardPE":0,"priceToBook":0,"priceToSales":0.01,"enterpriseToRevenue":5.07,"enterpriseToEbitda":-0.02,"pegRatio":0,"ebitda":-110180000,"ebitdaMargin":0,"freeCashflow":-57942500,"operatingCashflow":-100016000,"totalDebt":60226000,"debtToEquity":0,"currentRatio":2.25,"returnOnAssets":-59.9,"returnOnEquity":-777,"analystRating":"","recommendationKey":"none","numberOfAnalysts":4,"targetMeanPrice":8.75,"targetHighPrice":20,"targetLowPrice":4,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.1,"institutionHeldPercent":9.6,"sharesOutstanding":26832457,"floatShares":26817699,"sharesShort":939583,"shortRatio":0.8,"shortPercentOfFloat":3.5,"epsTrailing":-3.07,"epsForward":-2.61,"revenuePerShare":0.01,"bookValue":-0.41,"officers":[{"age":53,"name":"Dr. James E. Bradner M.D.","title":"Founder"},{"age":null,"name":"Dr. Nathanael S. Gray Ph.D.","title":"Scientific Founder & Member of Scientific Advisory Board"},{"age":null,"name":"Matthew  Foster","title":"Chief Restructuring Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.syros.com","phone":"617 744 1340"}}